Tumor Necrosis Factor-α T-857C (rs1799724) Polymorphism and Risk of Cancers: A Meta-Analysis

Table 2

Results of overall and subgroups analyses.

	No	T versus C			TT versus CC			TC versus CC			TT versus TC + CC			TT + TC versus CC
		OR [95% CI]	P(Z)		OR [95% CI]	P(Z)		OR [95% CI]	P(Z)		OR [95% CI]	P(Z)		OR [95% CI]	P(Z)
Gastric cancer
Total	9	1.12 [1.01, 1.25]	0.04	0.46	1.12 [0.79, 1.58]	0.52	0.20	1.16 [1.02, 1.33]	0.02	0.58	1.05 [0.75, 1.48]	0.78	0.15	1.16 [1.02, 1.32]	0.02	0.64
HWE, yes	7	1.01 [0.70, 1.45]	0.96	0.01	1.42 [0.95, 2.12]	0.08	0.42	1.16 [1.00, 1.34]	0.06	0.68	1.36 [0.89, 2.07]	0.16	0.40	1.18 [1.02, 1.36]	0.02	0.60
HWE, no	2	0.99 [0.79, 1.25]	0.96	0.64	0.57 [0.28, 1.16]	0.12	0.69	1.19 [0.76, 1.85]	0.45	0.11	0.51 [0.26, 1.03]	0.06	0.56	1.10 [0.81, 1.48]	0.54	0.27
Caucasian	3	1.01 [0.84, 1.21]	0.94	0.88	0.66 [0.35, 1.22]	0.18	0.63	1.13 [0.91, 1.40]	0.28	0.23	0.60 [0.33, 1.12]	0.11	0.52	1.07 [0.87, 1.32]	0.50	0.52
Asian	6	1.19 [1.04, 1.37]	0.01	0.38	1.46 [0.96, 2.22]	0.08	0.32	1.18 [1.00, 1.40]	0.04	0.63	1.38 [0.91, 2.09]	0.13	0.29	1.21 [1.03, 1.42]	0.02	0.56
HB	4	1.09 [0.93, 1.28]	0.28	0.15	1.04 [0.46, 2.34]	0.93	0.04	1.17 [0.96, 1.42]	0.12	0.42	0.98 [0.42, 2.27]	0.96	0.03	1.14 [0.95, 1.38]	0.16	0.41
PB	5	1.15 [0.99, 1.34]	0.06	0.71	1.34 [0.77, 2.32]	0.30	0.71	1.16 [0.97, 1.38]	0.10	0.44	1.26 [0.73, 2.18]	0.40	0.65	1.17 [0.99, 1.39]	0.07	0.54
PCR	3	1.22 [0.99, 1.50]	0.06	0.50	1.82 [0.89, 3.75]	0.10	0.90	1.17 [0.91, 1.49]	0.22	0.24	1.73 [0.84, 3.54]	0.13	0.83	1.21 [0.96, 1.54]	0.11	0.31
PCR-RFLP	3	1.16 [0.83, 1.61]	0.38	0.08	1.10 [0.32, 3.77]	0.88	0.02	1.21 [0.94, 1.55]	0.13	0.27	1.03 [0.29, 3.67]	0.97	0.01	1.18 [0.93, 1.50]	0.16	0.26
TaqMan	3	1.07 [0.90, 1.26]	0.44	0.89	0.89 [0.49, 1.61]	0.70	0.89	1.13 [0.93, 1.38]	0.22	0.63	0.85 [0.47, 1.53]	0.59	0.84	1.11 [0.92, 1.35]	0.28	0.73
HCC
Total	4	1.16 [0.89, 1.51]	0.27	0.08	1.65 [1.06, 2.57]	0.03	0.14	1.10 [0.90, 1.34]	0.35	0.33	1.61 [1.04, 2.49]	0.03	0.19	1.16 [0.96, 1.40]	0.13	0.16
HWE, yes	3	1.16 [0.77, 1.77]	0.48	0.05	2.29 [1.16, 4.51]	0.02	0.14	1.13 [0.87, 1.48]	0.37	0.19	2.21 [1.12, 4.34]	0.02	0.20	1.22 [0.94, 1.57]	0.13	0.09
HB	2	1.32 [0.90, 1.94]	0.15	0.04	2.13 [0.68, 6.67]	0.19	0.04	1.19 [0.95, 1.50]	0.14	0.24	2.00 [0.70, 5.69]	0.20	0.05	1.30 [0.90, 1.87]	0.16	0.10
PB	2	0.93 [0.66, 1.29]	0.65	0.90	1.06 [0.36, 3.09]	0.92	0.51	0.87 [0.59, 1.30]	0.51	0, 59	2.00 [0.70, 5.69]	0.86	0.48	0.89 [0.61, 1.31]	0.56	0.72
PCR	2	1.08 [0.86, 1.35]	0.51	0.66	1.20 [0.66, 2.17]	0.55	0.47	1.05 [0.80, 1.39]	0.71	0.90	1.18 [0.66, 2.12]	0.58	0.47	1.07 [0.83, 1.39]	0.60	0.78
PCR-RFLP	2	1.24 [0.70, 2.18]	0.46	0.02	2.35 [0.73, 7.51]	0.15	0.11	1.10 [0.64, 1.89]	0.74	0.07	2.45 [1.22, 4.93]	0.01	0.17	1.18 [0.65, 2.18]	0.58	0.04
Colorectal cancer
Total	4	1.01 [0.80, 1.27]	0.94	0.45	0.99 [0.40, 2.41]	0.97	0.62	1.01 [0.78, 1.31]	0.93	0.45	1.01 [0.41, 2.45]	0.99	0.69	1.01 [0.78, 1.30]	0.93	0.43
African	2	0.94 [0.68, 1.29]	0.69	0.85	0.83 [0.27, 2.54]	0.75	NA	0.94 [0.65, 1.36]	0.75	0.86	0.88 [0.29, 2.67]	0.82	NA	0.93 [0.65, 1.34]	0.71	0.85
Caucasian	2	1.01 [0.58, 1.76]	0.97	0.14	1.34 [0.30, 6.05]	0.70	NA	1.00 [0.54, 1.85]	1.00	0.13	1.29 [0.29, 5.84]	0.74	NA	1.00 [0.54, 1.86]	0.99	0.12
HB	3	1.06 [0.76, 1.48]	0.72	0.33	1.34 [0.30, 6.05]	0.70	NA	1.07 [0.77, 1.49]	0.69	0.31	1.29 [0.29, 5.84]	0.74	NA	1.08 [0.78, 1.49]	0.65	0.30
PB	1	0.92 [0.65, 1.31]	0.66	NA	0.83 [0.27, 2.54]	0.75	NA	0.93 [0.61, 1.41]	0.72	NA	0.88 [0.29, 2.67]	0.82	NA	0.92 [0.61, 1.38]	0.68	NA
PCR	1	0.71 [0.36, 1.38]	0.31	NA	NA	NA	NA	0.68 [0.34, 1.38]	0.29	NA	NA	NA	NA	0.68 [0.34, 1.38]	0.29	NA
TaqMan	3	1.06 [0.83, 1.35]	0.65	0.49	0.99 [0.40, 2.41]	0.97	0.62	1.08 [0.81, 1.43]	0.60	0.54	1.01 [0.41, 2.45]	0.99	0.69	1.07 [0.82, 1.41]	0.61	0.50
Cervical cancer
Total	3	0.75 [0.44, 1.29]	0.30	0.003	0.59 [0.23, 1.54]	0.28	0.11	0.77 [0.42, 1.42]	0.40	0.01	0.81 [0.47, 1.39]	0.44	0.20	0.75 [0.40, 1.40]	0.36	0.005
Prostate cancer
Total	2	1.05 [0.89, 1.24]	0.57	0.11	1.20 [0.62, 2.35]	0.59	0.74	1.04 [0.86, 1.25]	0.68	0.08	1.16 [0.60, 2.27]	0.66	0.85	1.05 [0.87, 1.25]	0.62	0.08

was derived from Chi-square statistics.